Cargando…

Safety of BA.4-5 or BA.1 bivalent mRNA booster vaccines: nationwide cohort study

OBJECTIVE: To examine the association between the omicron adapted bivalent mRNA covid-19 booster vaccines received as a fourth dose and risk of adverse events. DESIGN: Nationwide cohort study. SETTING: Denmark. PARTICIPANTS: 2 225 567 adults aged ≥50 years who received three covid-19 vaccine doses d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersson, Niklas Worm, Thiesson, Emilia Myrup, Hansen, Jørgen Vinsløv, Hviid, Anders
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group Ltd. 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10364193/ https://www.ncbi.nlm.nih.gov/pubmed/37491031 http://dx.doi.org/10.1136/bmj-2023-075015

Ejemplares similares

Comparative effectiveness of bivalent BA.4-5 and BA.1 mRNA booster vaccines among adults aged ≥50 years in Nordic countries: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2023)

Safety of heterologous primary and booster schedules with ChAdOx1-S and BNT162b2 or mRNA-1273 vaccines: nationwide cohort study
por: Andersson, Niklas Worm, et al.
Publicado: (2022)

Immunogenicity of BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2023)

Immunogenicity of the BA.5 Bivalent mRNA Vaccine Boosters
por: Collier, Ai-ris Y., et al.
Publicado: (2022)

Association Between Human Papillomavirus Vaccination and Primary Ovarian Insufficiency in a Nationwide Cohort
por: Hviid, Anders, et al.
Publicado: (2021)

Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants
por: Springer, David N., et al.
Publicado: (2023)

Antibody Response to Omicron BA.4–BA.5 Bivalent Booster
por: Wang, Qian, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Analysis of Thromboembolic and Thrombocytopenic Events After the AZD1222, BNT162b2, and MRNA-1273 COVID-19 Vaccines in 3 Nordic Countries
por: Dag Berild, Jacob, et al.
Publicado: (2022)

Neutralization against BA.2.75.2, BQ.1.1, and XBB from mRNA Bivalent Booster
por: Davis-Gardner, Meredith E., et al.
Publicado: (2022)

Neutralizing Antibody Response of the Wild-Type/Omicron BA.1 Bivalent Vaccine as the Second Booster Dose against Omicron BA.2 and BA.5
por: Kawasuji, Hitoshi, et al.
Publicado: (2023)

Bivalent COVID-19 booster vaccines and the absence of BA.5-specific antibodies
por: Carreño, Juan Manuel, et al.
Publicado: (2023)

Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2
por: Vasin, Andrey V, et al.
Publicado: (2023)

Durability of Booster mRNA Vaccine against SARS-CoV-2 BA.2.12.1, BA.4, and BA.5 Subvariants
por: Qu, Panke, et al.
Publicado: (2022)

Effectiveness of BA.1- and BA.4/BA. 5-Containing Bivalent COVID-19 mRNA Vaccines Against Symptomatic SARS-CoV-2 Infection During the BA.5-Dominant Period in Japan
por: Arashiro, Takeshi, et al.
Publicado: (2023)

Bivalent BNT162b2 mRNA original/omicron BA.4-5 booster vaccination: adverse reactions and inability to work compared with the monovalent COVID-19 booster
por: Wagenhäuser, Isabell, et al.
Publicado: (2023)

SARS-CoV-2 vaccination and myocarditis or myopericarditis: population based cohort study
por: Husby, Anders, et al.
Publicado: (2021)

Neutralization of BA.4–BA.5, BA.4.6, BA.2.75.2, BQ.1.1, and XBB.1 with Bivalent Vaccine
por: Zou, Jing, et al.
Publicado: (2023)

EE80 The Potential Clinical and Economic Benefits of a Next Generation Omicron-Containing (BA.1) Bivalent Sars-Cov-2 Booster Compared to First Generation Prototype Boosters in Germany Assuming BA.4/BA.5 Dominance
por: Maschio, M, et al.
Publicado: (2022)

Salivary antibodies induced by BA.4/BA.5-convalescence or bivalent booster Immunoglobulin vaccination protect against novel SARS-COV-2 variants of concern
por: Diem, Gabriel, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Safety and immunogenicity of the Pfizer/BioNTech SARS-CoV-2 mRNA third booster vaccine dose against the BA.1 and BA.2 Omicron variants
por: Seki, Yohei, et al.
Publicado: (2022)

Comparative Effectiveness of Bivalent (Original/Omicron BA.4/BA.5) COVID-19 Vaccines in Adults
por: Kopel, Hagit, et al.
Publicado: (2023)

Cell-mediated and Neutralizing Antibody Responses to the SARS-CoV-2 Omicron BA.4/BA.5–adapted Bivalent Vaccine Booster in Kidney and Liver Transplant Recipients
por: Fernández-Ruiz, Mario, et al.
Publicado: (2023)

Bivalent Omicron BA.1–Adapted BNT162b2 Booster in Adults Older than 55 Years
por: Winokur, Patricia, et al.
Publicado: (2023)

Brève : Avis positif pour l’UE du rappel bivalent Omicron BA.4/BA.5
por: Dalmat, Yann-Mickael
Publicado: (2022)

Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
por: Chalkias, Spyros, et al.
Publicado: (2023)

Neutralization of Omicron subvariants BA.1 and BA.5 by a booster dose of COVID-19 mRNA vaccine in a Japanese nursing home cohort
por: Itamochi, Masae, et al.
Publicado: (2023)

Effectiveness of mRNA-1273 vaccination against SARS-CoV-2 omicron subvariants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5
por: Tseng, Hung Fu, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BA.1, BA.4, and BA.5 by primary ChAdOx1 nCoV-19, mRNA-1273, MVC-COV1901 and booster mRNA-1273 vaccination
por: Liu, Yuag-Meng, et al.
Publicado: (2022)

Immunogenicity of the BA.1 and BA.4/BA.5 SARS-CoV-2 Bivalent Boosts: Preliminary Results from the COVAIL Randomized Clinical Trial
por: Branche, Angela R., et al.
Publicado: (2023)

Durability of the Neutralizing Antibody Response to mRNA Booster Vaccination Against SARS-CoV-2 BA.2.12.1 and BA.4/5 Variants
por: Qu, Panke, et al.
Publicado: (2022)

2337. Immunogenicity and Safety of a Heterologous Booster Dose of Omicron Subvariant (BA.1 and BA.5) and Bivalent SARS-CoV-2 Recombinant Spike Protein Vaccines: A Phase 3, Randomized, Clinical Trial
por: Bennett, Chijioke, et al.
Publicado: (2023)

Immunologic Effect of Bivalent mRNA Booster in Patients Undergoing Hemodialysis
por: Huth, Luca, et al.
Publicado: (2023)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Omicron variant neutralizing antibodies following BNT162b2 BA.4/5 versus mRNA-1273 BA.1 bivalent vaccination in patients with end-stage kidney disease
por: Yau, Kevin, et al.
Publicado: (2023)

Bivalent SARS-CoV-2 mRNA vaccines increase breadth of neutralization and protect against the BA.5 Omicron variant
por: Scheaffer, Suzanne M., et al.
Publicado: (2022)

Efficacy of mRNA-1273 and Novavax ancestral or BA.1 spike booster vaccines against SARS-CoV-2 BA.5 infection in non-human primates
por: Routhu, Nanda Kishore, et al.
Publicado: (2023)

Anatomy of Omicron BA.1 and BA.2 neutralizing antibodies in COVID-19 mRNA vaccinees
por: Andreano, Emanuele, et al.
Publicado: (2022)

Fifth bivalent omicron BA.4/BA.5 vaccination neutralization of SARS-CoV-2 in heart transplant recipients
por: Peled, Yael, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rg6mcakamap8hdkjgulbtg8t24